Biologics are medicines made from living cells that target specific parts of your immune system or specific proteins on cancer cells. Unlike conventional drugs, which are small synthetic molecules that spread broadly through your body, biologics are large, complex proteins designed to intercept one precise signal in a disease process. This precision is what makes them effective for conditions like rheumatoid arthritis, psoriasis, Crohn’s disease, and many cancers.
What Makes Biologics Different From Regular Drugs
Most medicines you pick up at a pharmacy are small-molecule drugs: compact chemical compounds with simple, predictable structures. They’re manufactured through chemical reactions in a lab, and every pill in a batch is identical to the last. Biologics are a fundamentally different category. They’re large proteins with complex three-dimensional shapes, produced inside living cells rather than through chemistry alone.
That complexity matters. A small-molecule drug has a straightforward structure that’s easy to replicate. A biologic has variable surface patterns and folding configurations that make manufacturing incredibly difficult. Scaling up production while keeping each batch equivalent to the last remains one of the biggest challenges in the industry. It’s also why biologics tend to be more expensive than conventional medications.
How They’re Made From Living Cells
Producing a biologic starts with genetic engineering. Scientists insert the gene for the desired protein (say, a specific antibody) into the DNA of mammalian cells using what’s called an expression vector. These engineered cells are then selected, grown, and optimized to produce large quantities of the target protein.
From there, the process scales up through a series of bioreactors, carefully controlled vessels where cells grow in nutrient-rich media. Temperature, oxygen levels, pH, and dozens of other variables have to be precisely managed to keep the cells healthy and the protein quality consistent. The whole journey, from small-scale cell culture to pilot-scale testing to full manufacturing, involves more biological variability than making a conventional drug, which is why quality control is so intensive. After the cells produce the protein, it goes through extensive purification to isolate the therapeutic molecule from everything else in the culture.
Targeting Inflammation in Autoimmune Disease
Your immune system uses signaling molecules called cytokines to coordinate inflammation. In autoimmune diseases, certain cytokines get overproduced, driving chronic inflammation that damages your joints, skin, gut, or other tissues. Biologics work by blocking specific cytokines or their receptors, essentially cutting one wire in the inflammatory circuit.
TNF inhibitors were among the first biologics to reach patients. TNF-alpha is a cytokine that triggers a cascade inside cells: it activates a group of transcription factors that switch on dozens of inflammatory genes. By binding TNF-alpha before it can reach its receptors, these biologics prevent that entire downstream cascade from firing. They’re widely used in rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Newer biologics go after different targets. IL-17 inhibitors block a cytokine that drives inflammation through a separate pathway, also ultimately activating inflammatory gene transcription but through different cellular machinery. IL-23 inhibitors work even further upstream, targeting a cytokine that helps produce the immune cells responsible for making IL-17 in the first place. This layered understanding of immune signaling is why doctors now have multiple biologic options if the first one doesn’t work for you.
How Biologics Fight Cancer
In oncology, biologics work through several distinct strategies, sometimes simultaneously. Monoclonal antibodies, the most common type, are engineered to recognize proteins found on the surface of cancer cells. Once they latch on, they can fight the tumor in multiple ways.
- Blocking growth signals. Some antibodies bind to receptors that cancer cells rely on for growth, preventing those receptors from sending signals and, in some cases, pulling the receptors off the cell surface entirely.
- Flagging cells for destruction. When antibodies coat a cancer cell, the tail end of each antibody acts as a beacon. Natural killer cells in your immune system recognize that beacon and directly destroy the tagged cell. Immune cells called macrophages can also engulf antibody-coated cells whole. On top of that, the antibodies can trigger a chain reaction in blood proteins called complement, which assembles a structure that punches holes in the cancer cell’s membrane.
- Delivering toxic payloads. Antibody-drug conjugates attach a potent chemotherapy agent to an antibody using a chemical linker. The antibody guides the drug specifically to tumor cells, reducing the widespread toxicity of traditional chemotherapy. A similar approach uses radioactive labels on antibodies to deliver targeted radiation directly to the tumor.
Why You Can’t Take Biologics as a Pill
Biologics are proteins, and proteins don’t survive the digestive system. Your stomach acid and digestive enzymes would break them apart long before they reached your bloodstream. This is the same reason you can’t eat insulin and expect it to work.
Instead, biologics are delivered by injection or infusion. Subcutaneous injections (under the skin, usually in the thigh or abdomen) have become the most common route for many conditions. The protein absorbs slowly from the tissue under your skin into your bloodstream, which means blood levels rise more gradually than with an intravenous infusion. How often you inject depends on the specific drug. Some require daily injections, but many modern biologics are dosed every one to four weeks. A few oncology biologics are given by infusion every three weeks to three months.
Intravenous infusions, given at a clinic or infusion center, deliver the drug directly into your bloodstream for immediate peak levels. This route is more common for cancer biologics and for the initial doses of some autoimmune treatments, with a possible switch to self-administered injections once you’re stable.
Why Biologics Need Refrigeration
Because biologics are proteins, they’re sensitive to environmental stress in ways that regular drugs aren’t. Their function depends on a precise three-dimensional shape held together by weak chemical bonds (hydrogen bonds and similar interactions). Heat, freezing, shaking, or even light can disrupt those bonds, causing the protein to unfold or clump together. Once that happens, the drug loses its effectiveness and can potentially trigger immune reactions.
Most biologics require storage between 2°C and 8°C (standard refrigerator temperature). Some, like certain vaccines, need deep-freeze storage as cold as negative 70°C. This “cold chain” requirement adds complexity to shipping and storage that conventional drugs simply don’t face, since small-molecule pills can typically sit at room temperature without degrading.
Biosimilars and Cost
When a biologic’s patent expires, other manufacturers can produce versions called biosimilars. These aren’t identical copies the way generic pills are, because the complex living-cell manufacturing process means no two production lines yield a perfectly identical protein. Instead, biosimilars must demonstrate that they are highly similar to the original with no meaningful clinical differences.
Some biosimilars earn an additional designation as “interchangeable,” which means a pharmacist can substitute them for the original biologic without needing approval from the prescribing doctor (depending on state laws). Not all biosimilars pursue this designation, and interchangeable status doesn’t mean the product is safer or more effective than a non-interchangeable biosimilar. It simply means the manufacturer completed additional testing to demonstrate that switching between the two products produces no difference in outcomes.
The Biologic Landscape Today
Biologics now represent roughly a quarter of all new drug approvals by the FDA. In 2025, 12 out of 46 newly approved drugs were biologics, which is actually a slight dip from the average of about 14.5 new biologics per year between 2018 and 2024. That earlier period saw biologics account for 29% of all approvals. The slight decline doesn’t signal a retreat from the technology; rather, the pipeline fluctuates year to year as different drugs complete their approval processes.
The trend over the past two decades has been clear: biologics have moved from a niche category to a central part of treatment for autoimmune diseases, cancers, blood disorders, and rare genetic conditions. Their precision targeting means fewer off-target side effects for many patients compared to broad-acting drugs, though they do carry real risks, particularly increased susceptibility to infections, since they suppress specific parts of the immune system that also help fight bacteria and viruses.